ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESR01

A Randomized, Double-Blind, Controlled, Multi-Center Trial of Colchicine in Calcium Pyrophosphate Deposition Disease

Active
Institution
BRIGHAM AND WOMEN'S HOSPITAL, MA
Principal investigator
Sara K. Tedeschi
Funding
$778K
Duration
2025–2030
Open portfolio

Moonbase score

Still being scored

Abstract

PROJECT SUMMARY/ABSTRACT Calcium pyrophosphate deposition disease (CPPD) is a painful inflammatory crystalline arthritis that afflicts 8-10 million Americans, but targeted treatments do not currently exist and there are very few studies on this common arthritis. Some patients with CPPD report improved joint symptoms with long-term colchicine 0.6mg daily (FDA-approved dose for gout), though we currently lack tools to predict which CPPD patients will benefit. The NLRP3 inflammasome plays a key role in the pathophysiology of CPPD and cardiovascular (CV) disease, and CV risk is up to two-fold higher in patients with CPPD than matched comparators. Understanding colchicine's impact on the NLRP3 inflammasome and downstream pathways will provide critical knowledge about mechanisms by which colchicine reduces CPPD symptoms and has tremendous

LOADING MOONBASE SCORE

R01NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESAging, Injury, Musculoskeletal, and Rheumatologic Disorders Study Section[AIMR]calciumdepositioninflammasomegoutarthritisrandomized double-blindlack toolsafflicts

Questions for BRIGHAM AND WOMEN'S HOSPITAL

Answered by the team behind this research.

No questions yet. Sign in to ask the first one

Related grants

Same institution, same topic, scored first.